This episode of Myeloma Matters reviews the latest data on bispecific antibody (bsAb) therapy for relapsed/refractory multiple myeloma (RRMM), as discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. Myeloma experts place research findings into clinical context and discuss strategies—including fixed-duration dosing—for preventing and managing bsAb-associated adverse events, which include cytokine release syndrome, neurotoxicity, and infection.

Topics of discussion:

• Highlights from ASCO and EHA 2024 - Teclistamab
• Highlights from ASCO and EHA 2024 - Elranatamab
• Highlights from ASCO and EHA 2024 - Linvoseltamab and ABBV-383
• GPRC5D-Directed Bispecific Antibody Therapy: Highlights From ASCO and EHA 2024
• Highlights from ASCO and EHA 2024: Infectious Complications with Bispecific Antibodies
• Highlights from ASCO and EHA 2024: Cevostamab
• Optimizing the Use of BCMA-Directed Bispecific Antibody Therapy
• Optimizing the Use of GPRC5D-Directed Bispecific Antibody Therapy

This episode is supported by Johnson & Johnson and Pfizer, Inc.

To view the virtual roundtable on the management of bispecific antibody–associated adverse events, visit myCME.

To learn more about the Multiple Myeloma Research Foundation (MMRF), visit www.themmrf.org.

Let your patients and their caregivers know about the FREE myeloma resources available on the MMRF Education Hub.